Abstract Number: 2028 • ACR Convergence 2020
Predictors of Maintaining Inactive Disease After Etanercept Withdrawal, and Regaining Inactive Disease Status After Flare and Retreatment, in Adults with Non-radiographic Axial Spondyloarthritis: Results from RE-EMBARK
Background/Purpose: RE-EMBARK was a phase 4, multicenter, open-label, 3-period study that evaluated etanercept (ETN) withdrawal and retreatment in adult patients with non-radiographic axial spondyloarthritis (nr-axSpA)…Abstract Number: 0221 • ACR Convergence 2020
Should We Use BioDMARDS in First Intention in Early Rheumatoid Arthritis? : Results at 5 Years from the ERA Louvain Brussels Cohort
Background/Purpose: Early effective treatment has led to major improvements in patients with rheumatoid arthritis (ERA). Low disease activity and remission are achieved earlier and in…Abstract Number: 0351 • ACR Convergence 2020
Ustekinumab-Treated Patients with Psoriatic Arthritis in a Real-world Study: Similar Clinical Responses and Treatment Persistence over One Year in Elderly and Younger Patients
Background/Purpose: In the PsABio study (NCT02627768), real-world data from patients with PsA showed comparable clinical results after treatment with ustekinumab (UST, an anti-p40 IL-12/23 inhibitor)…Abstract Number: 0478 • ACR Convergence 2020
Increasing Awareness of Advocacy During Early Career – a Web-Based Educational Program
Background/Purpose: In 2015, the American College of Rheumatology (ACR) began Advocacy 101 in person-education for Fellows in Training (FIT) and physicians to encourage participation in…Abstract Number: 0643 • ACR Convergence 2020
Use of Biologic Treatment and Risk to Be Admitted for COVID-19 Infection
Background/Purpose: To analyze the risk of admission for COVID19 infection and outcome of patients treated with b/tsDMARD from our center, to compare with all patients…Abstract Number: 0819 • ACR Convergence 2020
The Adherence Patterns Among Patients Using Infliximab Bio-originator and Biosimilar
Background/Purpose: Infliximab (INF) biosimilar was approved for multiple indications in U.S. in 2016. Although clinical trials have demonstrated that switching from infliximab bio-originator to its…Abstract Number: 0898 • ACR Convergence 2020
Inadequate Response Among Psoriatic Arthritis Patients Prescribed Advanced Therapy in a Real-world US Commercially Insured Population
Background/Purpose: The purpose of this analysis was to assess the frequency of inadequate response (IR) over 1 year associated with advanced therapy (AT) initiation among…Abstract Number: 1210 • ACR Convergence 2020
Patient-Reported Outcomes Measurement Information System (PROMIS) Assessment of Response to Treatment with Golimumab IV or Infliximab in Rheumatoid Arthritis Patients: Results from a Phase 4 Study
Background/Purpose: AWARE (Comparative & Pragmatic Study of Golimumab [GLM] Intravenous [IV] vs Infliximab [IFX] in RA) is a Phase 4 study designed to provide a…Abstract Number: 1374 • ACR Convergence 2020
Secukinumab in the Treatment of Dactylitis in Patients with Psoriatic Arthritis: Post Hoc Analysis Results from a Randomized Phase 3 Trial
Background/Purpose: Dactylitis is a key and frequent clinical manifestation of psoriatic arthritis (PsA)1 associated with significant disease burden and impaired function.2–3 Randomized controlled trials designed…Abstract Number: 1746 • ACR Convergence 2020
Association of Obesity with Treatment Response to Methotrexate or Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis
Background/Purpose: Obesity affects 30-40% of RA patients and is associated with higher clinical disease activity measures and progressive disability. Studies suggest that obesity may be…Abstract Number: 2052 • ACR Convergence 2020
Extended Follow-Up of Patients Recruited to a Randomized, Controlled Trial of Rituximab versus Azathioprine After Induction of Remission with Rituximab for Patients with ANCA-Associated Vasculitis and Relapsing Disease
Background/Purpose: Rituximab is an effective therapy for induction of remission in ANCA-associated vasculitis (AAV). However, the effect of rituximab is not sustained, and subsequent relapse…Abstract Number: 0222 • ACR Convergence 2020
tsDMARD Therapy Is Associated with More Initial Therapy Prolongations Compared to bDMARDs Both in Bionaive and Bioexperienced Patients with Rheumatoid Arthritis
Background/Purpose: The Tool for Administrative Reimbursement Drug Information Sharing (TARDIS) is an electronic platform combining the collection of data from all Belgian patients with Rheumatoid…Abstract Number: 0354 • ACR Convergence 2020
How Do TNF-alpha-Inhibitors in Medical History Affect Patient Reported Outcomes and Retention in Ankylosing Spondylitis Patients Treated with Secukinumab in Real World? – German Observational Study
Background/Purpose: Secukinumab (SEC), a fully human monoclonal antibody that selectively inhibits interleukin 17A, is approved for treatment of patients with ankylosing spondylitis (AS). However, there…Abstract Number: 0505 • ACR Convergence 2020
Secukinumab Provides Sustained Improvements in Clinical and Imaging Outcomes in Patients with Psoriatic Arthritis and Axial Manifestations: Results from the MAXIMISE Trial
Background/Purpose: Axial disease may affect up to 25–70% of psoriatic arthritis (PsA) patients, depending on the definition used. Current evidence on efficacy of biologics in…Abstract Number: 0713 • ACR Convergence 2020
Longitudinal Effectiveness of Abatacept in JIA: Results from an Ongoing JIA Registry
Background/Purpose: Abatacept is a selective T-cell co-stimulation modulator approved for use in JIA. Efficacy and safety of abatacept in patients with JIA has been demonstrated…
- « Previous Page
- 1
- …
- 46
- 47
- 48
- 49
- 50
- …
- 54
- Next Page »